Role of Early Bedside HIPEC as Adjuvant Treatment in Colorectal Peritoneal Metastasis
Objectives: Peritoneal metastasis (PM) is a poor prognostic factor for all malignancies and remains difficult to treat with systemic chemotherapy because of poor peritoneal vascularization, resulting in limited drug delivery and penetration into tissues. Our study aims to investigate the efficacy and safety of different locoregional treatment protocols with hyperthermic intraperitoneal chemotherapy (HIPEC), Early Peritoneal Chemotherapy (EPIC), Pressurized Intraperitoneal Chemotherapy (PIPAC) in the management of advanced colorectal cancer with metachronous PM.
Methods: A total of 42 patients were divided into three groups, as follows. Group A: After neoadjuvant systemic chemotherapy, 15 patients received cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) and then adjuvant systemic chemotherapy. Group B: After neoadjuvant systemic chemotherapy, 12 patients received CRS + HIPEC + early postoperative intraperitoneal chemotherapy for 5 postoperative days and then adjuvant systemic chemotherapy. Group C: After neoadjuvant chemotherapy, 15 patients received CRS + HIPEC and then an adjuvant bedside HIPEC on the 10th postoperative day combined with postoperative adjuvant chemotherapy.
Results: Patients in group A had a median overall survival (OS) of 33 months; however, log-rank tests showed that survival distributions of the three groups were not statistically significant different for both OS and disease-free survival.
Conclusion: In conclusion, CRS plus HIPEC remains an alternative to locoregional treatment in well-selected patients with PM in combination with systemic neoadjuvant and adjuvant chemotherapy.
1. National Cancer Institute. SEER Cancer Stat Facts: Colorectal cancer. Available at: https://seer.cancer.gov/statfacts/html/colorect.html. Accessed Nov 24, 2021.
2. Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum 2013;56:1373–80.
3. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212–22. [CrossRef]
4. Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: A population-based study. Dis Colon Rectum 2015;58:743–52. [CrossRef]
5. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699– 705. [CrossRef]
6. Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep 2016;6:29765.
7. Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res 1980;40:253–5.
8. Sugarbaker PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res 1996;81:149–68. [CrossRef]
9. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999;384:576– 87. [CrossRef]
10. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 2007;23:431–42. [CrossRef]
11. Hunter KW, Amin R, Deasy S, Ha NH, Wakefield L. Genetic insights into the morass of metastatic heterogeneity. Nat Rev Cancer 2018;18:211–23. [CrossRef]
12. Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet 2019;20:404–16.
13. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science 2016;352:169–75. [CrossRef]
14. Zajac O, Raingeaud J, Libanje F, Lefebvre C, Sabino D, Martins I, et al. Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nat Cell Biol 2018;20:296–306.
15. Demuytere J, Ceelen W, Van Dorpe J, Hoorens A. The role of the peritoneal microenvironment in the pathogenesis of colorectal peritoneal carcinomatosis. Exp Mol Pathol 2020;115:104442. [CrossRef]
16. Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 2018;37:2285–301. [CrossRef]
17. Spiliotis J, Vaxevanidou A, Halkia E, Hadjigeorgiou G, Datsis A. Reoperation combining re-cytoreductive surgery and re-HIPEC for recurrent peritoneal carcinomatosis. J BUON 2012;17:522–5.
18. Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ, et al; Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: A phase 2 randomized clinical trial. JAMA Surg 2021;156:710–20. [CrossRef]
19. Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, et al; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. [CrossRef]
20. Pereira F, Serrano A, Manzanedo I, Pérez-Viejo E, González-Moreno S, González-Bayón L, et al. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer 2022;22:536.
21. Zongyuan L, Xiaolin P, Hua J. Ascites and serial plasm circulating tumor DNA as a prognostic factor in peritoneal carcinomatosis after hyperthermic intraperitoneal chemotherapy. In Proceedings of the ASCO GastroIntestinal Cancer Symposium. San Francisco, USA: 20–22 January 2022. p. 661. [CrossRef]
22. Beagan JJ, Sluiter NR, Bach S, Eijk PP, Vlek SL, Heideman DAM, et al. Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: A clinical feasibility study. J Clin Med 2020;9:1738.
23. Baumgartner JM, Riviere P, Lanman RB, Kelly KJ, Veerapong J, Lowy AM, et al. Prognostic utility of pre- and postoperative circulating tumor DNA liquid biopsies in patients with peritoneal metastases. Ann Surg Oncol 2020;27:3259–67.
24. Spiliotis J, Kalles V, Prodromidou A, Raptis A, Ferfelis M, Christopoulou A, et al. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis. J BUON 2021;26:1260–5.